Compare GPRO & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRO | PYXS |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.6M | 166.6M |
| IPO Year | 2014 | 2021 |
| Metric | GPRO | PYXS |
|---|---|---|
| Price | $0.76 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 5.7M | 1.3M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.08 | 3.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $651,542,000.00 | $13,858,000.00 |
| Revenue This Year | $23.14 | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $0.97 |
| 52 Week High | $3.05 | $5.55 |
| Indicator | GPRO | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 56.09 |
| Support Level | $0.69 | $1.37 |
| Resistance Level | $0.85 | $2.92 |
| Average True Range (ATR) | 0.06 | 0.41 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 44.24 | 44.14 |
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.